Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00692055 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations

A Phase 1 study of Arthritis, sponsored by POZEN.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT00692055 is a Phase 1 study of Arthritis that has completed, run by POZEN. The registered enrollment target is 30 participants, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00692055, a Phase 1 study of Arthritis, has completed, sponsored by POZEN.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

We will evaluate the bioavailability of naproxen 375 mg in two formulations

Conditions Studied

Interventions

  • DRUG Naproxen
  • DRUG PN400

Study Locations (1)

Texas

  • - Austin

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-06
Est. Completion 2008-07
Phase Phase 1

Sponsor

POZEN

24 total trials

What the Registry Record Tells You About NCT00692055

The ClinicalTrials.gov registry entry for NCT00692055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Naproxen is the first listed.

NCT00692055 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00692055 about?

NCT00692055 is a clinical study titled "Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations". We will evaluate the bioavailability of naproxen 375 mg in two formulations

What is the current status of trial NCT00692055?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-06. Estimated completion is 2008-07.

What conditions does trial NCT00692055 study?

This clinical trial studies the following conditions: Arthritis.

What interventions are being tested in trial NCT00692055?

The interventions under investigation include: Naproxen (DRUG), PN400 (DRUG).

Who is sponsoring clinical trial NCT00692055?

This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00692055 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.